Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00192517 · ClinicalTrials.gov registry record · Phase 2
Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00192517 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 44 participants.
The verdict
NCT00192517, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the effects on disease activity, in the absence of systemic psoriasis therapy, of 4 mg/kg MEDI-522 versus placebo administered weekly by SC injection for 12 weeks.
Interventions
- OTHER Placebo
- DRUG MEDI-522
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2003-12 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00192517
The ClinicalTrials.gov registry entry for NCT00192517 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00192517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00192517 about?
NCT00192517 is a clinical study titled "Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis". The primary objective of this study is to compare the effects on disease activity, in the absence of systemic psoriasis therapy, of 4 mg/kg MEDI-522 versus placebo administered weekly by SC injection for 12 weeks.
What is the current status of trial NCT00192517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2003-12. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00192517?
The interventions under investigation include: Placebo (OTHER), MEDI-522 (DRUG).
Who is sponsoring clinical trial NCT00192517?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.